Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON--(BUSINESS WIRE)--Thermo Fisher Scientific is showcasing new mass spectrometry and chromatography instruments, software and workflows that enable customers to unlock deeper analytical insights, improve productivity and accelerate biological discovery. The company will highlight these innovations during the annual American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, from June 3-8, 2023, in Houston, Texas, in booth 700 at the George R. Brown Con.

Thermo Fisher Scientific Showcases Solutions for Accelerating Biological Discovery

WATERTOWN, Mass.--(BUSINESS WIRE)--Arranta Bio announced today that it has reached a settlement of its litigation with Thermo Fisher. The settlement follows an April 4, 2023 Delaware Court of Chancery ruling that Arranta Bio was not subject to any non-competition obligations in its 2020 supply agreement with Thermo Fisher to develop plasmids. The specific terms of the settlement were not disclosed. The company offered the following statement: “Arranta Bio is pleased with the settlement and has.

Statement From Arranta Bio on Settlement of Thermo Fisher Litigation

Thermo Fisher Scientific has experienced significant growth over the past 20 years, with a 14% CAGR in revenue and a 17% CAGR in adjusted EPS. Despite headwinds from the COVID-19 pandemic and inflation, the company maintains strong guidance for 2023, with a focus on rewarding shareholders through dividends and buybacks. TMO stock is currently trading at a premium but for good reasons. Today's price is still a good entry point but I would recommend to add only on weakness.

Buy Thermo Fisher, But With Caution

Thermo Fisher Scientific Inc. (NYSE:TMO ) Bernstein 39th Annual Strategic Decisions Conference Call May 31, 2023 11:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Eve Burstein - Bernstein Eve Burstein All right. Good morning, everyone.

Thermo Fisher Scientific Inc. (TMO) Bernstein 39th Annual Strategic Decisions Conference - (Transcript)

Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.

Thermo Fisher (TMO) Expands Manufacturing Facility in APAC

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its 2023 Investor Day today and provided an in-depth review of the Company's proven growth strategy and its industry-leading businesses: Life Science Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services. “Science is advancing at a rapid rate and we continue to bring high-impact innovation, and unique insights to differentiate.

Thermo Fisher Scientific Hosts 2023 Investor Day

Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.

Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Bernstein 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023 at 11:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world.

Thermo Fisher Scientific to Present at Bernstein 39th Annual Strategic Decisions Conference on May 31st, 2023

Thermo Fisher Scientific (NYSE:TMO) announced that the U.S. Food and Drug Administration (FDA) has cleared its Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR immunoassays.

Thermo Fisher receives FDA clearance for preeclampsia risk assessment tool

WALTHAM, Mass. & SINGAPORE--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has opened a new sterile drug facility in Singapore that will better enable customers to deliver new medicines and vaccines in the Asia-Pacific market. The new facility also marks a significant milestone and investment in pandemic preparedness for Singapore, which is fast emerging as a biomedical hub in the Asia-Pacific region. Established with assistance from the Singapore Economic Devel.

Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region

The U.S. Food and Drug Administration (FDA) has cleared the first test to detect women with risk of severe preeclampsia, a leading cause of pregnancy-related illness and death in the United States, Thermo Fisher Scientific Inc said on Friday.

Thermo Fisher's preeclampsia blood test wins FDA clearance

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers, the first and only immunoassays to receive breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, a severe pregnancy complication. Preeclampsia is a life-threa.

Thermo Fisher Scientific Announces FDA Clearance of Breakthrough Immunoassays to Aid in the Risk Assessment of Preeclampsia

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company's commitment to society and stakeholders and provides insight into its CSR progress and environmental, social and governance (ESG) efforts. “Our Mission to enable our customers to make the world healthier, cleaner and safer inspires our 125,000 colleagues every day. We are proud.

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

Thermo Fisher Scientific Inc. (TMO) CEO presents at BofA Securities 2023 Healthcare Conference Call (Transcript)

Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.

Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing

WALTHAM, Mass.--(BUSINESS WIRE)--Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associate.

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International Markets

Analog Devices

Applied Materials

Nanotechnology refers to technologies based on materials between 1 and 100 nanometers in size, which is the microscopic level. Accordingly, the production of such materials from nanotechnology stocks represent impressive upside, for those bullish on certain key industries.

The 3 Most Promising Nanotechnology Stocks to Buy

Stryker

Stalwarts are companies that have stood the test of time without trouble. Thermo Fisher's recent headwinds should have little impact on its long-term outlook.

Got $5,000? Buy These 2 Stalwart Stocks and Hold Them Forever

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 11:00 a.m. (EDT). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in.

Thermo Fisher Scientific to Present at BofA Securities 2023 Healthcare Conference on May 10th, 2023

Thermo Fisher is a dividend growth stock. However, it has an extremely low yield, which means it needs to shine in other areas. Thanks to a wide-moat, anti-cyclical business model, Thermo Fisher has pricing power and the ability to outperform the market with minimal volatility.

Thermo Fisher: Buying On Any Weakness

The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

Thermo Fisher Scientific Inc. (TMO) Q1 2023 Earnings Call Transcript.

Thermo Fisher Scientific Inc. (TMO) Q1 2023 Earnings Call Transcript

Shares of Thermo Fisher Scientific (NYSE:TMO) fell Wednesday morning after the company's first-quarter results revealed declining Covid-19 testing revenue. The Massachusetts-based company posted saw revenue decline 9% year-over-year from $11.82 billion to $10.71 billion, which beat Street expectations of $10.67 billion.

Thermo Fisher takes a hit on dwindling 1Q Covid testing revenue

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.03 per share, beating the Zacks Consensus Estimate of $4.95 per share. This compares to earnings of $7.25 per share a year ago.

Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates

Thermo Fisher's first-quarter adjusted earnings meet analysts' expectations even as Covid-19 testing revenue falls sharply.

News for Thermo Fisher Scientific Stock (TMO)